Hope, Research, and Progress in Brain Tumor Treatment

When a brain tumor enters a home, life gets divided into strange little pieces: scan days, waiting rooms, shuffling papers, medication schedules, fatigue, hope, fear, and the quiet work of trying to act normal in the middle of all of it.

And before anything else, it helps to set the record straight: people often use “brain tumor” and “brain cancer” interchangeably, but they are not always the same. Still, both can be serious because of where they grow, what they press on, and how much they can change a person’s life. The National Cancer Institute’s patient guide to adult central nervous system tumors explains that distinction simply and well.

What progress really looks like

Progress in brain tumor treatment does not always look dramatic from the outside. Sometimes it looks like a clearer diagnosis. Sometimes it looks like doctors learning more about a tumor’s genetic makeup so treatment can be better matched to the person in front of them. The National Cancer Institute’s overview of biomarker testing explains how tumor testing can help guide treatment decisions and, in some cases, connect patients to targeted therapies or clinical trials.

Recent FDA approvals show how targeted therapies are becoming more precise for some brain tumors. In August 2024, the FDA approved vorasidenib for certain grade 2 IDH-mutant astrocytomas and oligodendrogliomas after surgery. More recently, in August 2025, the FDA granted accelerated approval to dordaviprone (Modeyso) for adults and children with H3 K27M-mutant diffuse midline glioma whose disease had progressed after prior therapy. These approvals do not erase how hard these diagnoses can be. But they do show that research is moving, even in tumor types that have long needed better options.

At the same time, the National Cancer Institute’s CNS tumor treatment summary continues to point families toward established treatment paths and ongoing clinical trials. That kind of progress can feel slow when you are living inside the uncertainty, but it is still progress.

Why research and advocacy still matter

Brain and spine tumors are not one single disease. They include many different tumor types, grades, behaviors, and treatment realities. That is part of why research support and public advocacy matter so much: families need better options, better information, and faster movement than rarity and complexity often allow. The National Cancer Institute makes clear just how broad that category really is.

That is also why May matters. The National Brain Tumor Society identifies May as Brain Tumor Awareness Month, a time to amplify the voice of the brain tumor community and advocate for research funding and better care. For families walking through this, awareness is not abstract. It can shape what gets studied, what gets funded, and how quickly the next breakthrough arrives.

Supporting progress can look a few different ways. It can mean learning the language well enough to talk about these diagnoses accurately. It can mean supporting trusted research and advocacy organizations. It can mean asking good questions about treatment options and clinical trials. And it can mean staying present for families long after the first wave of concern has passed. Science needs funding. Families also need people who stay.

What families need while the science keeps moving

Here at A Week Away, we know treatment progress and daily family strain can exist at the same time. Our founder, Caleb Walker, lived with Stage III anaplastic ependymoma, a rare and aggressive cancer affecting the brain and spine. The foundation he built grew out of one deeply human truth: even in the middle of illness, people need room to breathe, rest, and feel like themselves again.

As Caleb said, “When you get away, you get to feel normal.” You can still feel that heart behind our work in What We Do and on Our Founder.

That truth still matters here in Lancaster County and across the Pennsylvania counties we serve. Families facing life-threatening illness do not only need good medicine. They need meals, help, quiet, margin, and sometimes a real change of scenery so their nervous system can come down for a minute. That is where we live as an organization. We do not fund medical research. We finance and coordinate Respite weeks for individuals and their loved ones who are dealing with a life-threatening illness, and we are currently accepting applications from patients in a defined group of Pennsylvania counties through our Receive A Week Away page.

There is real progress worth talking about. There is still real grief and uncertainty. And both can be true at once. If you want to come alongside families carrying that kind of weight, support A Week Away.